(Q27853118)

13 November 2016

title

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study (English)

1 reference

PubMed

PubMed publication ID

25586468

multicenter clinical trial

13 November 2016

main subject

phase II clinical trial

0 references

0 references

1 reference

12

Darell D Bigner

0 references

David A Reardon

4

object named as

David A Reardon

0 references

Nina A. Paleologos

5

object named as

Nina A Paleologos

0 references

author name string

James Schuster

1

0 references

Rose K Lai

2

0 references

Lawrence D Recht

3

0 references

Morris D Groves

6

0 references

Maciej M Mrugala

7

0 references

Randy Jensen

8

0 references

Joachim M Baehring

9

0 references

Andrew Sloan

10

0 references

Gary E Archer

11

0 references

Scott Cruickshank

13

0 references

Jennifer A Green

14

0 references

Tibor Keler

15

0 references

Thomas A Davis

16

0 references

Amy B Heimberger

17

0 references

John H Sampson

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

18

0 references

publication date

June 2015

0 references

published in

Neuro-Oncology

0 references

volume

17

0 references

issue

6

0 references

page(s)

854-61

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

IDH1 and IDH2 mutations in gliomas

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Microvesicles: messengers and mediators of tumor progression

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

29 September 2017

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU348

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOU348

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4483122

27 November 2018

Identifiers

DOI

10.1093/NEUONC/NOU348

1 reference

1 reference

1 reference

PubMed publication ID

25586468

1 reference